Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension

Back to Search
Print
Bookmark Trial

NCT01642407

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0375, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-17 year
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects weighing ≥8 kg.

- Subjects who have symptomatic pulmonary arterial hypertension due to one of the following conditions:

- Idiopathic pulmonary arterial hypertension; or

- Heritable pulmonary arterial hypertension; or

- Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts. If the defect(s) is repaired, the subject's condition should be stabilized hemodynamically; or

- Pulmonary arterial hypertension associated with d-transposition of the great arteries repaired within the first 30 days of life; or

- Pulmonary arterial hypertension in subjects who have undergone surgical repair of other congenital heart lesions and the condition should be stabilized hemodynamically and do not have clinically significant residual left-sided heart disease.

- Subjects with a mean pulmonary artery pressure ≥25 mmHg at rest, PCWP ≤15 mmHg, and PVRI ≥3 Wood units x m2. If PCWP is not available, then mean LA pressure ≤15 mmHg or LVEDP ≤15 mmHg in the absence of left atrial obstruction.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Left-sided heart disease.


- Subjects with Down syndrome.


- Subjects with Obstructive Sleep Apnea, regardless of treatment status.


- Pericardial constriction.


- Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid
or pulmonary regurgitation.


- Acutely decompensated heart failure within previous 30 days from screening.


- Subjects who have had an atrial septostomy within previous 6 months of screening.


- Subjects with hemodynamic instability or hypo- or hypertension at screening.


- Subjects with a history of stroke, myocardial infarction or life threatening
arrhythmia within 6 months of screening.


- Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or
Forced Vital Capacity ≤60% of normal) or history of severe lung disease.


- Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.


- Subjects with history of pulmonary embolism.


- Subjects with known hereditary degenerative retinal disorders (such as retinitis
pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).


- Subjects who are known to be HIV positive.


- Subjects with impairment of renal function (serum creatinine >2.5 × ULN) or hepatic
function (ALT and/or AST >3 × ULN; and/or bilirubin ≥2 mg/dL). Hematological
abnormalities (e.g., severe anemia, Hgb <10 g/dL, leukopenia, WBC <2500/µL).


- Subjects with severe hepatic dysfunction (Child-Pugh classification C).


- Change in class of medication for CHF or PAH within the 10 days prior to qualifying
right heart catheterization.


- Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in
any form.


- Subjects taking chronic arginine supplementation.


- Subjects who have received parenteral inotropic medication or parenteral vasodilators
within 30 days of Day 1.


- Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome
P450 3A4 inhibitors.


- Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1
are excluded. Subjects receiving an endothelin antagonist，PED5 inhibitor or,
prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except
for beraprost.


- Pregnant females; breastfeeding females; males and females of childbearing potential
not using highly effective contraception or not agreeing to continue highly effective
contraception for at least 28 days after last dose of investigational product.


- Current or past illicit drug use or alcoholism excepting if abstinence can be
documented for ≥1 year.


- Participation in another clinical trial of an investigational drug or device
(including placebo) within 30 days of screening for entry into the present study.


- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

ClinicalTrials.gov_Inqu[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension, Pulmonary HypertensionSafety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
NCT01642407
  1. Sagamihara, Kanagawa
  2. Suita, Osaka
  3. Ota-ku, Tokyo
  4. Setagaya-ku, Tokyo
  5. Shizuoka,
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionStudy Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796510
  1. Fountain Valley, California
  2. Cluj Napoca,
  3. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionSitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
NCT00795639
  1. Fountain Valley, California
  2. Mather, California
  3. Sacramento, California
  4. Englewood, Colorado
  5. Littleton, Colorado
  6. Gainesville, Florida
  7. Sarasota, Florida
  8. Weston, Florida
  9. Chicago, Illinois
  10. Olathe, Kansas
  11. Towson, Maryland
  12. Boston, Massachusetts
  13. Omaha, Nebraska
  14. New Brunswick, New Jersey
  15. Islandia, New York
  16. Stony Brook, New York
  17. Chapel Hill, North Carolina
  18. Cincinnati, Ohio
  19. Cleveland, Ohio
  20. Lancaster, Pennsylvania
  21. Lancaster, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Pittsburgh, Pennsylvania
  24. Providence, Rhode Island
  25. Charleston, South Carolina
  26. Dallas, Texas
  27. Houston, Texas
  28. San Antonio, Texas
  29. Temple, Texas
  30. Lynchburg, Virginia
  31. Richmond, Virginia
  32. Milwaukee, Wisconsin
  33. Buenos Aires,
  34. Buenos Aires,
  35. Buenos Aires,
  36. Buenos Aires,
  37. Sofia,
  38. Sofia,
  39. Veliko Turnovo,
  40. Temuco,
  41. Changsha, Hunan
  42. Xi'an, Shanxi
  43. Beijing,
  44. Shanghai,
  45. Shanghai,
  46. Bogotá, Cundinamarca
  47. Escazu, San Jose
  48. Praha 2,
  49. Santo Domingo, República Dominicana
  50. Santo Domingo,
  51. Guatemala,
  52. Hyderabad, Andhera Pradesh
  53. Hyderabad, Andhra Pradesh
  54. Ahmedabad, Gujarat
  55. Surat, Gujarat
  56. Vadodara, Gujarat
  57. Pune, Maharashtra
  58. Coimbatore, Tamil Nadu
  59. Madurai, Tamil Nadu
  60. Georgetown, Penang
  61. Mexico, DF
  62. Mexico, DF
  63. Monterrey, Nuevo Leon
  64. Lima,
  65. Lima,
  66. Quezon City,
  67. Cluj Napoca,
  68. Iasi,
  69. Moscow,
  70. Moscow,
  71. Saint-Petersburg,
  72. Saint-Petersburg,
  73. Saint-Petersburg,
  74. Riyadh,
  75. Belgrade,
  76. Bratislava,
  77. Cape Town, Western Cape
  78. Cape Town,
  79. Johannesburg,
  80. Stellenbosch,
  81. Bangkoknoi, Bangkok
  82. Bangkok,
  83. Istanbul, Fatih,
  84. Kyiv,
  85. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Pulmonary Arterial Hypertension, Pulmonary HypertensionStudy Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
NCT00796666
  1. Fountain Valley, California
  2. Gainesville, Florida
  3. Weston, Florida
  4. Boston, Massachusetts
  5. Omaha, Nebraska
  6. Chapel Hill, North Carolina
  7. Cincinnati, Ohio
  8. Cleveland, Ohio
  9. Providence, Rhode Island
  10. Houston, Texas
  11. San Antonio, Texas
  12. Milwaukee, Wisconsin
  13. Buenos Aires,
  14. Buenos Aires,
  15. Buenos Aires,
  16. Buenos Aires,
  17. Sofia,
  18. Temuco,
  19. Changsha, Hunan
  20. Beijing,
  21. Shanghai,
  22. Shanghai,
  23. Bogotá, Cundinamarca
  24. Praha 2,
  25. Hyderabad, Andhra Pradesh
  26. Hyderabad, Andhra Pradesh
  27. Ahmedabad, Gujarat
  28. Ahmedabad, Gujarat
  29. Surat, Gujarat
  30. Vadodara, Gujarat
  31. Pune, Maharashtra
  32. Coimbatore, Tamil Nadu
  33. Madurai, Tamil Nadu
  34. Georgetown, Penang
  35. Monterrey, Nuevo Leon
  36. Lima,
  37. Cluj Napoca,
  38. Iasi,
  39. Moscow,
  40. Moscow,
  41. Saint-Petersburg,
  42. Saint-Petersburg,
  43. Belgrade,
  44. Johannesburg,
  45. Bangkoknoi, Bangkok
  46. Istanbul, Fatih,
  47. Kyiv,
  48. Kyiv,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Official Title  ICMJE A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension
Brief Summary

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.

Sildenafil was approved by the European Commission for the treatment of PAH in pediatric patients in May 2011, making it the first agent to be approved for the treatment of children with PAH. The approval was based on the largest placebo-controlled study to be conducted in this population. The recommended dose in pediatric patients aged 1 year to 17 years old is 10 mg TID in patients ? 20 kg and 20 mg TID for patients > 20 kg. Higher doses are not recommended in pediatrics patients.

This study is an open-label, multi-center study to investigate safety, efficacy and pharmacokinetics of sildenafil citrate in Japanese pediatric patients with PAH.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pulmonary Arterial Hypertension
  • Hypertension, Pulmonary
Intervention  ICMJE Drug: Sildenafil
Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ? 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Study Arms  ICMJE Experimental: Sildenafil
Intervention: Drug: Sildenafil
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 3, 2017)		6
Original Estimated Enrollment  ICMJE
 (submitted: July 13, 2012)		10
Actual Study Completion Date  ICMJE March 12, 2018
Actual Primary Completion Date May 20, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects weighing ?8 kg.
  • Subjects who have symptomatic pulmonary arterial hypertension due to one of the following conditions:
  • Idiopathic pulmonary arterial hypertension; or
  • Heritable pulmonary arterial hypertension; or
  • Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts. If the defect(s) is repaired, the subject's condition should be stabilized hemodynamically; or
  • Pulmonary arterial hypertension associated with d-transposition of the great arteries repaired within the first 30 days of life; or
  • Pulmonary arterial hypertension in subjects who have undergone surgical repair of other congenital heart lesions and the condition should be stabilized hemodynamically and do not have clinically significant residual left-sided heart disease.
  • Subjects with a mean pulmonary artery pressure ?25 mmHg at rest, PCWP ?15 mmHg, and PVRI ?3 Wood units x m2. If PCWP is not available, then mean LA pressure ?15 mmHg or LVEDP ?15 mmHg in the absence of left atrial obstruction.

Exclusion Criteria:

  • Left-sided heart disease.
  • Subjects with Down syndrome.
  • Subjects with Obstructive Sleep Apnea, regardless of treatment status.
  • Pericardial constriction.
  • Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation.
  • Acutely decompensated heart failure within previous 30 days from screening.
  • Subjects who have had an atrial septostomy within previous 6 months of screening.
  • Subjects with hemodynamic instability or hypo- or hypertension at screening.
  • Subjects with a history of stroke, myocardial infarction or life threatening arrhythmia within 6 months of screening.
  • Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital Capacity ?60% of normal) or history of severe lung disease.
  • Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
  • Subjects with history of pulmonary embolism.
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
  • Subjects who are known to be HIV positive.
  • Subjects with impairment of renal function (serum creatinine >2.5 × ULN) or hepatic function (ALT and/or AST >3 × ULN; and/or bilirubin ?2 mg/dL). Hematological abnormalities (e.g., severe anemia, Hgb <10 g/dL, leukopenia, WBC <2500/µL).
  • Subjects with severe hepatic dysfunction (Child-Pugh classification C).
  • Change in class of medication for CHF or PAH within the 10 days prior to qualifying right heart catheterization.
  • Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form.
  • Subjects taking chronic arginine supplementation.
  • Subjects who have received parenteral inotropic medication or parenteral vasodilators within 30 days of Day 1.
  • Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome P450 3A4 inhibitors.
  • Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1 are excluded. Subjects receiving an endothelin antagonist?PED5 inhibitor or, prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except for beraprost.
  • Pregnant females; breastfeeding females; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 28 days after last dose of investigational product.
  • Current or past illicit drug use or alcoholism excepting if abstinence can be documented for ?1 year.
  • Participation in another clinical trial of an investigational drug or device (including placebo) within 30 days of screening for entry into the present study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Year to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01642407
Other Study ID Numbers  ICMJE A1481298
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP